L-156602

Cat. No.:	HY-16384
CAS No.:	125228-51-5
Molecular Formula:	$C_{38}H_{64}N_8O_{13}$
Molecular Weight:	840.96
Target:	Complement System
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	L-156602 is a C5a receptor antagonist. L-156602 inhibits inflammation, and the migration of monocytes and neutrophils to the infiltrating site in mouse inflammatory models. L-156602 suppresses the efferent phase of delayed-type hypersensitivity (DTH)[1][2].
IC_{50} & Target	C5a receptor[1][2]

In Vivo

L-156602 (0.1-0.5 mg/kg, i.p., once daily for 3 days) suppressed inflammation significantly in CDF1 mice induced by Concanavalin A (HY-P2149) and BALB/c mice induced by Muramyl dipeptide (MDP) (HY-127090)[1][2].
L-156602 (0.2-0.5 mg/kg, i.p.) suppressed the infiltration of mononuclear leukocytes and neutrophils into the site of inflammation in PCI-induced inflammation of DBA/1 mice[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Concanavalin A-induced inflammation of CDF1 mice[1][2]
Dosage:	0.1, 0.5 mg/kg, once daily for 3 days
Administration:	Intraperitoneal injection (i.p.)
Result:	Suppressed the swelling completely after 4 h at 0.1 mg/kg, and the effect was still statistical after 24 h at 0.5 mg/kg. Reduced the number of migrated leukocytes. Suppressed the migration of neutrophils, macrophages and lymphocytes non-specifically.

Animal Model:	MDP-induced acute joint inflammation of BALB/c mice[1]
Dosage:	0.25, 0.5 mg/kg, once daily for 3 days
Administration:	Intraperitoneal injection (i.p.)
Result:	Suppressed adjuvant arthritis although a slight reduction of body weight at the dose of 0.5 mg/kg after 24 h.

Animal Model:	0.5% PCI-induced inflammation of DBA/1 mice[2]
Dosage:	0.2, 0.5 mg/kg
Administration:	Intraperitoneal injection (i.p.)
Result:	Suppressed ear swelling significantly and the infiltration of mononuclear leukocytes and neutrophils into the site of inflammation.

Animal Model:	5% PCI-induced inflammation of DBA/1 mice[2]
Dosage:	0.4 mg/kg
Administration:	Intraperitoneal injection (i.p.)
Result:	Suppressed the infiltration of mononuclear leukocytes and neutrophils into the site of inflammation non-specifically.

REFERENCES

[1]. Tsuji RF, et al. Effects of L-156,602, a C5a receptor antagonist, on mouse experimental models of inflammation. Biosci Biotechnol Biochem. 1992 Dec;56(12):2034-6.

[2]. Tsuji RF, et al. Anti-inflammatory effects and specificity of L-156,602: comparison of effects on concanavalin A and zymosan-induced footpad edema, and contact sensitivity response. Immunopharmacology. 1995 Feb;29(1):79-87.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA